Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (261-270 of 294) with videos related to

Pageof 30
Sort By:
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2019
Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder CancerVenkatrao Vantaku, Jianrong Dong, Chandrashekar R Ambati, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Trials|October 4, 2023
Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responsesAndrew R DiNardo, Moshe Arditi, Ashish M Kamat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Open Forum Infectious Diseases|January 28, 2025
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 InfectionSantiago Carrero Longlax, Kent J Koster, Ashish M Kamat, et al.
European Urology|September 30, 2019
A Consensus Molecular Classification of Muscle-invasive Bladder CancerAurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al.
Pageof 30

Showing results (261-270 of 294) with videos related to

Sort By:
Pageof 30
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2019
Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder CancerVenkatrao Vantaku, Jianrong Dong, Chandrashekar R Ambati, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Trials|October 4, 2023
Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responsesAndrew R DiNardo, Moshe Arditi, Ashish M Kamat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Open Forum Infectious Diseases|January 28, 2025
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 InfectionSantiago Carrero Longlax, Kent J Koster, Ashish M Kamat, et al.
European Urology|September 30, 2019
A Consensus Molecular Classification of Muscle-invasive Bladder CancerAurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al.
Pageof 30